Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
作者信息
Wermke Martin, Kraus Sabrina, Ehninger Armin, Bargou Ralf C, Goebeler Maria-Elisabeth, Middeke Jan Moritz, Kreissig Carla, von Bonin Malte, Koedam Jan, Pehl Michael, Bornhäuser Martin, Einsele Hermann, Ehninger Gerhard, Cartellieri Marc
机构信息
Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
National Center for Tumor Diseases, Dresden, Germany.
出版信息
Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759.
Abstract
摘要
相似文献
1
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759.
2
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Oncoimmunology. 2021 Jul 8;10(1):1945804. doi: 10.1080/2162402X.2021.1945804. eCollection 2021.
3
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Br J Haematol. 2023 Sep;202(6):1137-1150. doi: 10.1111/bjh.18971. Epub 2023 Jul 17.
4
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Mol Ther Oncolytics. 2020 Apr 29;17:408-420. doi: 10.1016/j.omto.2020.04.009. eCollection 2020 Jun 26.
5
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Blood Cancer J. 2016 Aug 12;6(8):e458. doi: 10.1038/bcj.2016.61.
6
How close are we to CAR T-cell therapy for AML?
Best Pract Res Clin Haematol. 2019 Dec;32(4):101104. doi: 10.1016/j.beha.2019.101104. Epub 2019 Oct 18.
7
Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Viruses. 2021 Jul 14;13(7):1365. doi: 10.3390/v13071365.
8
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005400.
9
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
Front Immunol. 2020 Aug 18;11:1787. doi: 10.3389/fimmu.2020.01787. eCollection 2020.
10
[Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].
Rinsho Ketsueki. 2022;63(10):1446-1453. doi: 10.11406/rinketsu.63.1446.
引用本文的文献
1
The bispecific innate cell engager AFM28 eliminates CD123 leukemic stem and progenitor cells in AML and MDS.
Nat Commun. 2025 Aug 21;16(1):7793. doi: 10.1038/s41467-025-63069-y.
2
[Advances in the application strategies of CRISPR/Cas9 technology in chimeric antigen receptor T cell therapy for hematological malignancies].
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):481-488. doi: 10.3760/cma.j.cn121090-20240911-00343.
3
CAR-T cell therapy for cancer: current challenges and future directions.
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
4
CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?
Curr Oncol. 2025 May 30;32(6):322. doi: 10.3390/curroncol32060322.
5
CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.
Int J Mol Sci. 2025 May 23;26(11):5024. doi: 10.3390/ijms26115024.
6
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
7
T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02652-0.
8
Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended-Gate Field-Effect-Transistor Biosensors.
Small Sci. 2025 Feb 3;5(5):2400515. doi: 10.1002/smsc.202400515. eCollection 2025 May.
9
Tolerogenic Therapies in Cardiac Transplantation.
Int J Mol Sci. 2025 Apr 23;26(9):3968. doi: 10.3390/ijms26093968.
10
CAR T-cells for acute leukemias in children: current status, challenges, and future directions.
Cancer Metastasis Rev. 2025 Apr 23;44(2):47. doi: 10.1007/s10555-025-10261-7.
本文引用的文献
1
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Blood Adv. 2020 Aug 11;4(15):3528-3549. doi: 10.1182/bloodadvances.2020001920.
2
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000845.
3
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Mol Ther Oncolytics. 2020 Apr 29;17:408-420. doi: 10.1016/j.omto.2020.04.009. eCollection 2020 Jun 26.
4
How close are we to CAR T-cell therapy for AML?
Best Pract Res Clin Haematol. 2019 Dec;32(4):101104. doi: 10.1016/j.beha.2019.101104. Epub 2019 Oct 18.
5
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Oncoimmunology. 2019 Sep 7;8(11):1659095. doi: 10.1080/2162402X.2019.1659095. eCollection 2019.
6
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Haematologica. 2019 Jul;104(7):1302-1308. doi: 10.3324/haematol.2018.208751. Epub 2019 Jun 20.
7
The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Immunol Lett. 2019 Jul;211:13-22. doi: 10.1016/j.imlet.2019.05.003. Epub 2019 May 12.
8
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
9
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
10
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3.
Zotero 插件